suggests that KRAS G12V but not KRAS G13D mutations may prevent gallbladder cancer patients from responding to anti-EGFR therapy, KRAS G13D mutation as sensitive but G12V as resistant to anti-EGFR therapy. The gene discussed is EGFR; the disease is gallbladder cancer.